Talphera (TLPH) FCF Margin (2011 - 2025)

Talphera (TLPH) posted quarterly FCF Margin of 251000.0% for Q3 2025, down 1853.03% quarter-over-quarter from 12851.85% in Q1 2025.

Talphera (TLPH) FCF Margin (2011 - 2025) Analysis & Trends

Talphera's FCF Margin history runs 14 years deep, the most recent figure standing at 251000.0% for Q3 2025.

In Q3 2025, FCF Margin changed N/A year-over-year to 251000.0%; the TTM figure through Mar 2026 stood at 1129400.0% (down 108025185.0% YoY), while the FY2025 annual figure was 40585.71%, changed N/A from the prior year.
FCF Margin for Q3 2025 stood at 251000.0%, down from 12851.85% in the prior quarter.
The five-year high for FCF Margin was 242.76% in Q3 2021, with the low at 401600.0% in Q4 2021.
The 4-year median for FCF Margin is 2107.91% (2023), against an average of 61726.81%.
Peak annual rise in FCF Margin reached 183565 bps in 2021, while the deepest fall reached 40052168 bps in 2021.
Talphera's FCF Margin stood at 401600.0% in 2021, then surged by 99 bps to 2041.4% in 2022, then soared by 31 bps to 1405.34% in 2023, then sank by 17760 bps to 251000.0% in 2025.
Business Quant data shows TLPH's FCF Margin at 251000.0% in Q3 2025, 12851.85% in Q1 2025, and 1405.34% in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-	-
2	Teva Pharmaceutical Industries	43.07 Bn	39.42 Bn	2.15 Bn	7.41%
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn	21.80%
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn	14.87%
5	United Therapeutics	22.19 Bn	19.53 Bn	683.80 Mn	26.25%
6	Viatris	18.68 Bn	17.79 Bn	1.46 Bn	8.76%
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	13.41%
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	17.84%
9	Dr Reddys Laboratories	10.12 Bn	9.96 Bn	-	-
10	Talphera	89.95 Mn	89.95 Mn	-	-

Download Data